BioNTech News

BioNTech | 6-K: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Apr 8 07:17 ET

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 25 15:44 ET

BioNTech | 6-K: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Mar 20 07:17 ET

BioNTech | 6-K: BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

Mar 11 09:06 ET

BioNTech | 6-K: BioNTech Announces Planned Retirement of Sean Marett

Mar 7 08:44 ET

BioNTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Feb 15 16:15 ET

BioNTech | 6-K: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 8 06:10 ET

BioNTech | 6-K: Biontech and Dualitybio Receive Fda Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

Jan 31 07:51 ET

BioNTech | 6-K: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

Jan 22 00:00 ET

BioNTech | 6-K: BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

Dec 21, 2023 16:02 ET

BioNTech | 6-K: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Dec 18, 2023 16:22 ET

BioNTech | 6-K: BioNTech and Australia’s State of Victoria Sign Agreement on Strategic Partnership to Strengthen mRNA Ecosystem

Dec 7, 2023 20:17 ET

BioNTech | 6-K: Innovation Series Day 2023 Presentation

Nov 7, 2023 08:03 ET

BioNTech | 6-K: Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Oct 26, 2023 16:08 ET

BioNTech | 6-K: BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

Oct 23, 2023 16:16 ET

BioNTech | 6-K: BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

Oct 16, 2023 06:14 ET

BioNTech | 6-K: Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs

Oct 16, 2023 06:03 ET

BioNTech | 6-K: Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Sep 11, 2023 16:03 ET

BioNTech | 6-K: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

Aug 30, 2023 16:12 ET

BioNTech | 6-K: BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer

Aug 14, 2023 08:34 ET